Clinical Trial

Safe Threshold to Discontinue Phototherapy in Hemolytic Disease of Newborn

Recruiting
View on ClinicalTrials.gov →
Summary
We hypothesized that adopting a lower rather than a higher threshold for phototherapy discontinuation will be associated with reduced rates of rebound hyperbilirubinemia in term and late preterm neonates with hemolytic disease of newborn. Objectives: The investigators aimed to compare the safety of implementing low-threshold, compared to high- threshold, of TSB for phototherapy interruption in term and late preterm neonates with hemolytic disease of newborn.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2020-01-02; most recent amendment 2025-01-01.
Trial Details
NCT Number NCT04218318
Lead Sponsor Ministry of Health, Saudi Arabia
Conditions Hemolytic Disease of Newborn, Neonatal Hyperbilirubinemia
Enrollment 84 participants
Start Date 2019-10-01
Primary Completion 2026-10-31 (estimated)
Study Completion 2027-01-01 (estimated)
Updated on ClinicalTrials.gov 2025-01-03